top of page

FDA Authorizes 24 VELO Pouch Products: PMTA Takeaways

Writer: John Blubee
John Blubee
Nov 2
3 min read

On October 30, 2026, the U.S. Food and Drug Administration announced that it authorized the marketing of 24 VELO nicotine pouch products from Modoral Brands Inc., an operating company of Reynolds American Inc. These are nicotine pouches, not e-liquids, but the decision is a useful data point for anyone who manufactures, brands, or distributes ENDS products, because it shows how FDA is describing the evidentiary bar in the premarket tobacco application (PMTA) process.


What FDA Authorized


According to FDA's announcement, the authorization covers eight product names sold in three types of packaging, which adds up to 24 unique products. The eight names fall under two lines: VELO Mini Pouch (Crema, Lime, Orange Crema, and Passion Fruit) and VELO Mini Pouch 2 (Crema, Lime, Orange Crema, and Cinnamon). All of the products contain 4 mg of nicotine. Reynolds American's own announcement of the authorization lists the same eight products, flavors, and strength.


FDA also states that all three packaging types authorized incorporate certified child-resistant packaging. The agency says the products were reviewed under its nicotine pouch pilot program.


How FDA Described Its Reasoning


FDA's announcement explains that a product must be reviewed for the risks and benefits to the U.S. population as a whole, and that authorization requires that a product's public health benefits outweigh its risks. In this case, the agency said the pouches contain lower levels of harmful and potentially harmful constituents (HPHCs) than cigarettes and smokeless tobacco, and no measurable levels of several carcinogenic HPHCs.


The agency also considered whether adults 21 and older who use tobacco could benefit by completely switching to a potentially lower-risk product. FDA stressed that adults should switch completely, noting that dual use does not provide the same degree of health benefit. That framing, authorization tied to adult tobacco users switching away from cigarettes, is consistent with how FDA has described its public health standard in other premarket decisions.


What It Means for E-Liquid Brands


The first takeaway is that the PMTA pathway remains the gate for any flavored nicotine product sold in the U.S., and FDA decisions are made product by product. An authorization for nicotine pouches is not an authorization for any ENDS product, and it should not be read as a prediction of how FDA will act on any pending e-liquid or vape application. Brands should treat it as an illustration of the kind of public health reasoning the agency documents when it does issue a marketing order.


The second takeaway concerns packaging and adult-only positioning. FDA specifically highlighted certified child-resistant packaging in this announcement. For e-liquid brands, child-resistant closures, clear labeling, and marketing that is directed only at adult smokers are baseline expectations, and they are easy for regulators, retailers, and payment partners to evaluate.


Practical Steps for Vape Brands and Distributors


Whatever the status of your own applications, the fundamentals of a defensible product file are the same. Consistent formulations make it possible to show that what is on the shelf matches what was characterized. Batch-level records make it possible to trace a finished bottle back to its ingredients and production run. Stable specifications for nicotine strength make label claims verifiable. Brands that keep this documentation organized are better positioned to respond to retailer, distributor, or regulator questions without a scramble.


Distributors and wholesale buyers can apply the same logic when vetting suppliers. Ask for documentation of formulation control, nicotine content verification, and packaging specifications before onboarding a new line, and confirm the regulatory status of each product you intend to carry in the states where you sell.


Working With Nova Manufacturing


Nova Manufacturing is a U.S. e-liquid contract manufacturer. We produce to standardized formulations, keep batch documentation for every run, and operate to GMP-quality standards, so that vape brands, distributors, and wholesale buyers have a consistent and well-documented product. All of our work is intended for adult nicotine users. If you are planning a new line or looking for a more reliable manufacturing partner, get in touch with our team to talk through your formulations, volumes, and documentation needs.


Sources: FDA CTP Newsroom announcement of October 30, 2026 on the marketing authorization of VELO nicotine pouches; Reynolds American, October 30, 2026; Tobacco Insider industry highlights for October 24 to 30, 2026.

 
 
 

Recent Posts

See All

Comments


bottom of page